Literature DB >> 12941727

Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA.

Angela Galler1, Grit Müller, Reinhard Schinzel, Juergen Kratzsch, Wieland Kiess, Gerald Münch.   

Abstract

OBJECTIVE: Advanced glycation end products (AGEs) are a complex and heterogenous group of proteins that are formed by nonenzymatic glycation in a series of reactions. It is hypothesized that they may play a role in the pathogenesis of diabetes-related complications; at present, however, their exact biological role is scarcely understood. Clinical studies so far have shown that serum levels of AGEs are correlated with clinical stages of diabetes complications such as retinopathy and nephropathy. This study was performed in children and adolescents with type 1 diabetes to examine the putative role of serum AGEs in respect to metabolic control and diabetes complications in relation to a number of clinical and laboratory parameters. RESEARCH DESIGN AND METHODS: We studied 99 children and adolescents up to the age of 20 years with type 1 diabetes and 60 control subjects. Serum levels of AGEs were measured with two different methods [fluorescence spectroscopy and Nepsilon-(carboxymethyl)lysine (CML) enzyme-linked immunosorbent assay] and correlated with clinical data, such as age, diabetes duration, BMI, and long-term metabolic control determined by HbA(1c), and laboratory parameters, such as serum lipids.
RESULTS: Serum levels of fluorescent AGEs, but not of CML-AGEs, in children and adolescents with type 1 diabetes were significantly higher compared with control subjects. There was an age-dependent increase of fluorescent AGEs in children and adolescents with diabetes that was not seen in healthy children and adolescents. Levels of fluorescent AGEs in patients with diabetes between 13 and 16 years of age correlated positively with HbA(1c) levels. No significant association between levels of AGEs and diabetes duration was found. Children and adolescents with diabetes and high serum triglycerides had significantly higher serum levels of fluorescent AGEs. Children and adolescents with diabetes between the age of 13 and 16 years with high levels of LDL had significantly higher levels of fluorescent AGEs.
CONCLUSIONS: In this study we demonstrated a clear age-dependent increase of fluorescent AGEs but not of CML-AGEs in children and adolescents with diabetes type 1. Moreover we showed a strong association between serum AGEs and serum triglycerides and cholesterol. The observed effect may be caused by a loss of optimal regulation of lipid metabolism. It could suggest a link between triglycerides and formation of AGEs. This new and interesting finding and its impact on metabolic control and the development of diabetes complications should be examined in the future.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941727     DOI: 10.2337/diacare.26.9.2609

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  21 in total

Review 1.  New molecular insights in diabetic nephropathy.

Authors:  Ionel Alexandru Checheriţă; Gina Manda; Mihai Eugen Hinescu; Ileana Peride; Andrei Niculae; Ştefana Bîlha; Angelica Grămăticu; Luminiţa Voroneanu; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

2.  Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions.

Authors:  Yeoungjee Cho; Janine Büchel; Sonja Steppan; Jutta Passlick-Deetjen; Carmel M Hawley; Goce Dimeski; Margaret Clarke; David W Johnson
Journal:  Perit Dial Int       Date:  2015-10-01       Impact factor: 1.756

3.  Risk factors for clinically significant macular edema in a multi-ethnics population with type 2 diabetes.

Authors:  Ong Ming Jew; Mohammadreza Peyman; Tan Chen Chen; Subrayan Visvaraja
Journal:  Int J Ophthalmol       Date:  2012-08-18       Impact factor: 1.779

4.  Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man.

Authors:  Melinda T Coughlan; Sheila K Patel; George Jerums; Sally A Penfold; Tuong-Vi Nguyen; Karly C Sourris; Sianna Panagiotopoulos; Piyush M Srivastava; Mark E Cooper; Louise M Burrell; Richard J Macisaac; Josephine M Forbes
Journal:  Am J Nephrol       Date:  2011-08-26       Impact factor: 3.754

Review 5.  Advanced glycation end products, oxidative stress and diabetic nephropathy.

Authors:  Sho-Ichi Yamagishi; Takanori Matsui
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

6.  Effectiveness of arginase inhibitors against experimentally induced stroke.

Authors:  Waleed Barakat; Ahmad Fahmy; Mohamed Askar; Sherif El-Kannishy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-29       Impact factor: 3.000

7.  Advanced glycation end products (AGEs) in relation to atherosclerotic lipid profiles in middle-aged and elderly diabetic patients.

Authors:  Jin-Biou Chang; Nain-Feng Chu; Jhu-Ting Syu; An-Tsz Hsieh; Yi-Ren Hung
Journal:  Lipids Health Dis       Date:  2011-12-06       Impact factor: 3.876

8.  RAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activation.

Authors:  Yuhuang Li; Shuying Liu; Zhengyu Zhang; Qingbo Xu; Fukang Xie; Jingjing Wang; Suning Ping; Chen Li; Zhaojing Wang; Min Zhang; Jintao Huang; Dadi Chen; Liping Hu; Chaohong Li
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

9.  Pomegranate (Punicagranatum) juice decreases lipid peroxidation, but has no effect on plasma advanced glycated end-products in adults with type 2 diabetes: a randomized double-blind clinical trial.

Authors:  Golbon Sohrab; Pooneh Angoorani; Maryam Tohidi; Hadi Tabibi; Masoud Kimiagar; Javad Nasrollahzadeh
Journal:  Food Nutr Res       Date:  2015-09-08       Impact factor: 3.894

10.  Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus.

Authors:  Claudia Luévano-Contreras; Ma Eugenia Garay-Sevilla; Kazimierz Wrobel; Juan M Malacara; Katarzyna Wrobel
Journal:  J Clin Biochem Nutr       Date:  2012-12-06       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.